Letters to the Editor

Tsavaris, Nicolas; Zinelis, Andreas; Tsoutsos, H.; Kosmidis, P.

doi:10.1111/j.1365-2796.1991.tb00488.x

Cited by 3 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, the blinding method and allocation sequence concealment were not reported in this study. In the non-RCT study, [8] MINORS global scores were 14 by summing all 12 item scores, indicating a low quality.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Naproxen for the treatment of neoplastic fever

Zhang¹,

Lin³

et al. 2019

Medicine

View full text Add to dashboard Cite

Background: The effect of naproxen on the treatment of neoplastic fever is still unclear. A systematic review and meta-analysis were performed to investigate the effect of naproxen in the treatment of cancer fever or suspicion. Besides, the latest and most convincing evidence was provided for the earlier use of naproxen in treating cancer patients with fever of unknown origin. Methods: A literature review was conducted to identify all published studies on the naproxen for the treatment of neoplastic fever. Electronic databases (eg, PUBMED, EMBASE and the Cochrane Library) were searched until October 2018. Data were extracted, and the risk of bias was assessed by 2 authors independently. Standard meta-analyses on the rate of successful treatment were conducted using a random-effects model, and relative risks were calculated with 95% confidence intervals (CIs). Results: A total of 15 studies, recruiting 582 participants, were included, which were 1 randomized controlled trial (RCT), 1 non-RCT, 3 cross-sectional studies, and 10 case-series studies. The result of our meta-analysis revealed that the success rate on the treatment of neoplastic fever using naproxen was 94.1% (95% CI: 87.6%–97.3%). The success rate of the suspected neoplastic fever was 79.8%; for fever of unknown origin, it also reached 67.7%. In this meta-analysis, the success rate was 98.1% (95% CI: 95.0%–99.3%) in the dosage of 250 mg twice a day. Besides, a small dose of 125 mg naproxen, 375 mg twice a day and 250 mg 3 times a day were also useful. The result of the subgroup analysis revealed that the difference was not statistically significant in the treatment success rate for solid tumors and hematologic malignant. Conclusions: The result of our meta-analysis suggested that naproxen exhibited a highly successful rate for the treatment of neoplastic fever. Besides, naproxen was also satisfactory in improving symptoms of suspected neoplastic fever and fever of unknown origin. The earlier use of naproxen might be able to mitigate cancer patient's suffering and enhanced their quality of life. These findings, however, rely primarily on observational data and should be interpreted rigorously. Further well-conducted trials are required to assess naproxen for the treatment of neoplastic fever.

show abstract

Section: Resultsmentioning

confidence: 99%

“…However, it was reported that paraneoplastic fever in hematologic malignant was more sensitive to naproxen administration during the first day. [8] The mean temperatures significantly dropped in hematologic malignant than that in solid tumors.…”

Section: Discussionmentioning

confidence: 99%